Migraine
📧 Sign up to get email alerts when something new happens for Migraine.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-02-21FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Dr. Reddy's Laboratories Ltd)
The FDA approved a supplemental application for divalproex sodium from Dr. Reddy's Laboratories Ltd, indicating an update to its labeling. T…
-
CLINICAL_TRIALS trial_result · 2020-02-21Clinical Trial Update: A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine [Phase 2]
Phase 2 study of galcanezumab (LY2951742) in Japanese participants with episodic migraine completed; results posted in 2020.
-
FDA approval · 2020-02-20FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Dr. Reddy's Laboratories Ltd)
The FDA approved a supplemental application for divalproex sodium submitted by Dr. Reddy's Laboratories Ltd. This action denotes an approved…
-
FDA approval · 2020-02-15FDA Approved: AIMOVIG — Supplemental Application (Amgen Inc)
FDA approved a supplemental application for AIMOVIG (erenumab-aooe) from Amgen.
-
FDA approval · 2020-02-14FDA Approved: TOPIRAMATE — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for topiramate submitted by Upsher-Smith Laboratories, LLC, resulting in an update to the produc…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-02-09FDA Approved: RIZATRIPTAN BENZOATE — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved a supplemental application for rizatriptan benzoate from Unichem Pharmaceuticals (USA), Inc., enabling the generic product to b…
-
CLINICAL_TRIALS trial_result · 2020-02-07Clinical Trial Update: Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention [Phase 2]
Phase 2 trial update evaluating AMG 301 for prevention of chronic or episodic migraine has completed with results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-02-05Clinical Trial Update: Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine [Phase 2]
Phase 2 trial update on IONIS-PKKRx for preventive treatment of chronic migraine; study completed with posted results.
-
FDA approval · 2020-02-02FDA Approved: RIZATRIPTAN BENZOATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva's supplemental application for rizatriptan benzoate, enabling a generic version of the acute migraine medication to reach …
-
FDA approval · 2020-01-30FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' supplemental application for divalproex sodium, resulting in an approved change to the product u…
-
FDA approval · 2020-01-29FDA Approved: RIZATRIPTAN BENZOATE — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved Rising Pharma Holdings, Inc.'s supplemental application for Rizatriptan Benzoate, enabling the marketing of a generic rizat…
-
FDA approval · 2020-01-29FDA Approved: RIZATRIPTAN BENZOATE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
The FDA approved Glenmark's supplemental application for rizatriptan benzoate, a migraine medication, under an ANDA, authorizing changes to …
-
FDA approval · 2020-01-27FDA Approved: ZOLMITRIPTAN — Supplemental Application (Alembic Pharmaceuticals Inc.)
FDA approved a supplemental application for zolmitriptan from Alembic Pharmaceuticals Inc. under an ANDA.
-
FDA approval · 2020-01-27FDA Approved: AJOVY — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for AJOVY (fremanezumab) submitted by Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2020-01-22FDA Approved: RIZATRIPTAN BENZOATE — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for Rizatriptan Benzoate (Ascend Laboratories, LLC) under the existing ANDA, indicating an update to…
-
CLINICAL_TRIALS trial_result · 2020-01-22Clinical Trial Update: Peripheral Nerve Block and Topiramate in the Treatment of Medication Overuse Headaches [NA]
A completed clinical trial evaluating peripheral nerve block and topiramate for medication overuse headaches with results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-01-21Clinical Trial Update: Comparison of Therapeutic Effects of Greater Occipital Nerve Block, Topiramate, and Flunarizine on Episodic Migraine [NA]
Clinical trial comparing greater occipital nerve block, topiramate, and flunarizine for episodic migraine has completed with results posted.
-
FDA approval · 2020-01-14FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved a supplemental application for divalproex sodium submitted by Lupin Pharmaceuticals, Inc.
-
FDA approval · 2020-01-13FDA Approved: ZOLMITRIPTAN — Supplemental Application (Glenmark Pharmaceuticals Inc.,USA)
The FDA approved Glenmark's supplemental application for zolmitriptan, a generic product. This action confirms the continued market availabi…
-
CLINICAL_TRIALS trial_result · 2020-01-10Clinical Trial Update: The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants [Phase 1]
Phase 1 trial assessing the effects of lasmiditan on simulated driving performance in healthy participants.
-
FDA approval · 2020-01-09FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
The FDA approved a supplemental application for divalproex sodium submitted by Unichem Pharmaceuticals (USA), Inc.
-
CLINICAL_TRIALS trial_result · 2020-01-09Clinical Trial Update: A Study of LY2951742 in Participants With Migraine [Phase 2]
Phase 2 trial update for LY2951742 in migraine shows completed status with results posted.
-
FDA approval · 2020-01-08FDA Approved: ZOLMITRIPTAN — Supplemental Application (Cipla USA Inc.)
FDA approved Cipla USA Inc.'s supplemental application for zolmitriptan under the ANDA framework.
-
FDA approval · 2020-01-07FDA Approved: DIHYDROERGOTAMINE MESYLATE — Original Application (Provepharm Inc.)
FDA approved an original ANDA for dihydroergotamine mesylate from Provepharm Inc., providing a generic option for treating migraines. This r…
-
FDA approval · 2020-01-06FDA Approved: PROPRANOLOL HYDROCHLORIDE — Original Application (Lannett Company, Inc.)
FDA approved the original application for propranolol hydrochloride from Lannett Company, Inc., enabling a generic version to be marketed.